Research ExplorerPublicationsPlatinum disposition after intraarterial and intravenous inf...

Platinum disposition after intraarterial and intravenous infusion of cisplatin for osteosarcoma. Cooperative Osteosarcoma Study Group COSS.

Standard

Platinum disposition after intraarterial and intravenous infusion of cisplatin for osteosarcoma. Cooperative Osteosarcoma Study Group COSS. / Bielack, S S; Erttmann, Rudolf; Looft, G; Purfürst, C; Delling, G; Winkler, K; Landbeck, G.

In: CANCER CHEMOTH PHARM, Vol. 24, No. 6, 6, 1989, p. 376-380.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bielack, SS, Erttmann, R, Looft, G, Purfürst, C, Delling, G, Winkler, K & Landbeck, G 1989, 'Platinum disposition after intraarterial and intravenous infusion of cisplatin for osteosarcoma. Cooperative Osteosarcoma Study Group COSS.', CANCER CHEMOTH PHARM, vol. 24, no. 6, 6, pp. 376-380. <http://www.ncbi.nlm.nih.gov/pubmed/2676224?dopt=Citation>

APA

Bielack, S. S., Erttmann, R., Looft, G., Purfürst, C., Delling, G., Winkler, K., & Landbeck, G. (1989). Platinum disposition after intraarterial and intravenous infusion of cisplatin for osteosarcoma. Cooperative Osteosarcoma Study Group COSS. CANCER CHEMOTH PHARM, 24(6), 376-380. [6]. http://www.ncbi.nlm.nih.gov/pubmed/2676224?dopt=Citation

Vancouver

Bielack SS, Erttmann R, Looft G, Purfürst C, Delling G, Winkler K et al. Platinum disposition after intraarterial and intravenous infusion of cisplatin for osteosarcoma. Cooperative Osteosarcoma Study Group COSS. CANCER CHEMOTH PHARM. 1989;24(6):376-380. 6.

Bibtex

@article{3beed069e5f549a3bdf205633e28aed0,
title = "Platinum disposition after intraarterial and intravenous infusion of cisplatin for osteosarcoma. Cooperative Osteosarcoma Study Group COSS.",
abstract = "Preoperative chemotherapy according to the COSS 86 protocol, including two courses of cisplatin, was used for high-risk osteosarcoma. Patients were randomised to receive either intraarterial (i.a.) or intravenous (i.v.) cisplatin infusions. As measured by flameless atomic absorption spectroscopy (FAAS), platinum (Pt) levels in serum, ultrafiltrate, and urine did not show a decrease in systemic drug availability with i.a. administration. Tumors were surgically removed 3 weeks after the last cisplatin dose and analysed for Pt content and response to chemotherapy. A correlation could not be demonstrated between Pt levels in tumor tissue samples and the mode of CDDP application or extent of tumor cell destruction.",
author = "Bielack, {S S} and Rudolf Erttmann and G Looft and C Purf{\"u}rst and G Delling and K Winkler and G Landbeck",
year = "1989",
language = "Deutsch",
volume = "24",
pages = "376--380",
journal = "CANCER CHEMOTH PHARM",
issn = "0344-5704",
publisher = "Springer",
number = "6",

}

RIS

TY - JOUR

T1 - Platinum disposition after intraarterial and intravenous infusion of cisplatin for osteosarcoma. Cooperative Osteosarcoma Study Group COSS.

AU - Bielack, S S

AU - Erttmann, Rudolf

AU - Looft, G

AU - Purfürst, C

AU - Delling, G

AU - Winkler, K

AU - Landbeck, G

PY - 1989

Y1 - 1989

N2 - Preoperative chemotherapy according to the COSS 86 protocol, including two courses of cisplatin, was used for high-risk osteosarcoma. Patients were randomised to receive either intraarterial (i.a.) or intravenous (i.v.) cisplatin infusions. As measured by flameless atomic absorption spectroscopy (FAAS), platinum (Pt) levels in serum, ultrafiltrate, and urine did not show a decrease in systemic drug availability with i.a. administration. Tumors were surgically removed 3 weeks after the last cisplatin dose and analysed for Pt content and response to chemotherapy. A correlation could not be demonstrated between Pt levels in tumor tissue samples and the mode of CDDP application or extent of tumor cell destruction.

AB - Preoperative chemotherapy according to the COSS 86 protocol, including two courses of cisplatin, was used for high-risk osteosarcoma. Patients were randomised to receive either intraarterial (i.a.) or intravenous (i.v.) cisplatin infusions. As measured by flameless atomic absorption spectroscopy (FAAS), platinum (Pt) levels in serum, ultrafiltrate, and urine did not show a decrease in systemic drug availability with i.a. administration. Tumors were surgically removed 3 weeks after the last cisplatin dose and analysed for Pt content and response to chemotherapy. A correlation could not be demonstrated between Pt levels in tumor tissue samples and the mode of CDDP application or extent of tumor cell destruction.

M3 - SCORING: Zeitschriftenaufsatz

VL - 24

SP - 376

EP - 380

JO - CANCER CHEMOTH PHARM

JF - CANCER CHEMOTH PHARM

SN - 0344-5704

IS - 6

M1 - 6

ER -